{"id":"placebo-for-quetiapine-xr","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3188993","moleculeType":"Small molecule","molecularWeight":"883.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to the placebo effect, natural disease progression, or regression to the mean. Placebos are essential for blinded trial design to isolate the true therapeutic benefit of the investigational drug.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:19.415Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 trial for quetiapine XR efficacy evaluation"}]},"trialDetails":[{"nctId":"NCT00457197","phase":"PHASE4","title":"Quetiapine for Bipolar Disorder and Alcohol Dependence","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-03","conditions":"Bipolar Disorder, Alcohol Dependence","enrollment":90},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT01725282","phase":"PHASE2","title":"Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-12-14","conditions":"Major Depressive Disorder","enrollment":172},{"nctId":"NCT03207438","phase":"PHASE4","title":"Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2006-04","conditions":"Depressive Disorder, Major","enrollment":1790},{"nctId":"NCT00498628","phase":"PHASE2","title":"Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2007-12","conditions":"Alcoholism, Alcohol Abuse","enrollment":224},{"nctId":"NCT00880919","phase":"PHASE3","title":"Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2008-06","conditions":"Borderline Personality Disorder","enrollment":95},{"nctId":"NCT00671853","phase":"PHASE3","title":"Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2008-04","conditions":"Bipolar Disorder, Anxiety, Anxiety Disorders","enrollment":120},{"nctId":"NCT00619892","phase":"PHASE4","title":"A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2008-02","conditions":"Panic Disorder","enrollment":26},{"nctId":"NCT00253266","phase":"PHASE4","title":"Venlafaxine Augmentation in Treatment Resistant Depression","status":"COMPLETED","sponsor":"Max-Planck-Institute of Psychiatry","startDate":"2008-04","conditions":"Depression","enrollment":126},{"nctId":"NCT00688818","phase":"NA","title":"Quetiapine in Co-Morbid Depressive and Anxiety Disorders","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2008-06","conditions":"Major Depressive Disorder, Dysthymic Disorder, Anxiety Disorders","enrollment":108},{"nctId":"NCT00746421","phase":"PHASE4","title":"Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder","status":"TERMINATED","sponsor":"Emory University","startDate":"2010-01","conditions":"Bipolar Disorder, Cognitive Impairment","enrollment":32},{"nctId":"NCT00631748","phase":"NA","title":"Quetiapine for the Reduction of Cocaine Use","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2008-02","conditions":"Cocaine Dependence, Cocaine Abuse, Cocaine Addiction","enrollment":60},{"nctId":"NCT00893841","phase":"PHASE2","title":"Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride","status":"COMPLETED","sponsor":"Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.","startDate":"2009-02","conditions":"Bipolar Depression","enrollment":96},{"nctId":"NCT01213836","phase":"PHASE4","title":"Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-11","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT00389064","phase":"PHASE3","title":"Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Anxiety Disorders","enrollment":450},{"nctId":"NCT00723970","phase":"PHASE4","title":"Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression","status":"COMPLETED","sponsor":"McMaster University","startDate":"2007-06","conditions":"Major Depressive Disorder, Insomnia, Hot Flashes","enrollment":40},{"nctId":"NCT00983320","phase":"PHASE4","title":"Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2008-04","conditions":"Fibromyalgia","enrollment":52},{"nctId":"NCT00675896","phase":"PHASE4","title":"A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome","status":"COMPLETED","sponsor":"Dr Alexander McIntyre Inc.","startDate":"2007-04","conditions":"Major Depression","enrollment":120},{"nctId":"NCT00352469","phase":"PHASE4","title":"Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety","status":"COMPLETED","sponsor":"Creighton University","startDate":"2006-02","conditions":"Alcoholism, Anxiety Disorders, Generalized Anxiety Disorder","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":107,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo for Seroquel XR"],"phase":"phase_3","status":"active","brandName":"Placebo for quetiapine XR","genericName":"Placebo for quetiapine XR","companyName":"University Hospitals Cleveland Medical Center","companyId":"university-hospitals-cleveland-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in phase 3 trial for quetiapine XR efficacy evaluation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}